Respiratory Syncytial Virus hospitalizations burden: a nation-wide population-based analysis, 2000-2017
Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract morbidity, particularly among young infants and children1. It can also cause lower respiratory tract morbidity in elderly individuals, particularly in patients with chronic pulmonary and cardiac diseases or immunodeficiency2. Presently, the only available modality for preventing illness due to RSV consists of passive immunization with a humanized monoclonal antibody (Palivizumab) directed towards the RSV F protein3. However, it is restricted to specific high-risk infants and children4, and requires substantial financial resources5.
Source: Journal of Infection - Category: Infectious Diseases Authors: Aharona Glatman-Freedman, Zalman Kaufman, Yael Applbaum, Rita Dichtiar, Ada Steiman, Ethel-Sherry Gordon, Lital Keinan-Boker, Tamy Shohat, Ziona Haklai Source Type: research
More News: Infectious Diseases | Respiratory Medicine